Precipio Inc
NASDAQ:PRPO

Watchlist Manager
Precipio Inc Logo
Precipio Inc
NASDAQ:PRPO
Watchlist
Price: 30.7 USD 9.66% Market Closed
Market Cap: $54.6m

Precipio Inc
Other Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Precipio Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Precipio Inc
NASDAQ:PRPO
Other Operating Expenses
-$11.8m
CAGR 3-Years
8%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Other Operating Expenses
$40m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CVS Health Corp
NYSE:CVS
Other Operating Expenses
-$43.9B
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Guardant Health Inc
NASDAQ:GH
Other Operating Expenses
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Precipio Inc
Glance View

Market Cap
54.6m USD
Industry
Health Care

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in Omaha, Nebraska and currently employs 55 full-time employees. The company went IPO on 2000-07-18. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.

PRPO Intrinsic Value
11.09 USD
Overvaluation 64%
Intrinsic Value
Price $30.7

See Also

What is Precipio Inc's Other Operating Expenses?
Other Operating Expenses
-11.8m USD

Based on the financial report for Dec 31, 2025, Precipio Inc's Other Operating Expenses amounts to -11.8m USD.

What is Precipio Inc's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
-3%

Over the last year, the Other Operating Expenses growth was -1%. The average annual Other Operating Expenses growth rates for Precipio Inc have been 8% over the past three years , -3% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett